Exploristics Clinical Data Analysis and Modelling

At Exploristics we provide innovative analysis solutions to maximise the information derived from your clinical data. We offer a unique expertise in the exploratory analysis and clinical application of biomarkers, pharmacogenomics, imaging and observational data.

The team at Exploristics offers more than a statistical analysis and reporting service. We take pride in using our analytical skills and scientific expertise to help you make informed decisions. We work closely with our customers to understand their data analysis needs and to provide practical solutions. So far, we have worked successfully with pharmaceutical, biotechnology, medical diagnostics and devices companies as well as healthcare providers. Our service is friendly and cost-effective and our work is compliant with GCP / ICH guidelines.

Clinical data exploration, mining and modelling

Our broad experience using multiple analysis techniques enables us to perform a wide range of exploratory data analyses. These allow us to gain a thorough understanding of the data and to detect meaningful patterns in the data.

Furthermore, we can develop mathematical models that describe complex processes and then study the behaviour of those models under different conditions. This approach can save time and money by allowing you to evaluate your options by running virtual experiments. These methods are useful for solving complex problems that involve numerous factors, such as the design of complex studies.

Clinical application of biomarkers and pharmacogenomics data

We are experts in the clinical application of biomarkers and pharmacogenomics (PGx). We help you integrate these data into clinical development, evaluate your portfolio to find opportunities for these data, design experiments, analyse data and provide information on how to use the results. We also work with you to enable the integration of these data into your research programs.

Other clinical data analysis support

We also provide analysis support for the following study types and activities: epidemiology; pre-clinical studies; translational medicine; experimental medicine; medical devices; pharmacovigilance; in-licensing support; and training, education and consultancy.

Biomarker data management, visualisation and analysis tools

Exploristics has partnered with OmicSoft Corporation to supply and distribute biomarker data management, visualisation and analysis tools in Europe. OmicSoft has designed software that is easy to use for the bench scientists, but powerful enough to be used by the bioinformatician or statistician. Exploristics offers two software packages: Array Studio and Array Server.

Statistics and visualisation for biomarker data analysis

Array Studio provides state-of-the-art statistics and visualisation for the analysis of high dimensional data. Array Studio supports all popular microarray platforms (Affymetrix, Agilent, Illumina, etc.), as well as SNP / genotype platforms (Affymetrix, Illumina, etc.) and CNV platforms (Affymetrix, Illumina and Agilent). Array Studio provides a full workflow for importing and normalisation of data, quality control, analysis, and clustering and pattern analysis.

Microarray / SNP / copy number variation (CNV) project integration

Array Server is an enterprise solution, allowing users to store, share, search and integrate their microarray / SNP / CNV projects. Array Server supports any number of high dimensional platforms, including the same platforms supported by Array Studio. Users can search by meta data, use search-by-gene functions, and can even profile gene regions across multiple studies.

Make an enquiry

Exploristics Ltd

Exploristics Images

Products and Services


White Papers

Related Projects

Bydureon® BCise™ for the Treatment of Type-2 Diabetes

Bydureon® BCise™ (exenatide extended-release) is an injectable suspension containing a glucagon-like peptide-1 (GLP-1) receptor agonist. 

4th May 2018

Bavencio (avelumab) for the Treatment of Metastatic Merkel Cell Carcinoma

Bavencio® (avelumab) is a human PD-L1 monoclonal antibody indicated for the treatment of metastatic Merkel-cell carcinoma (MCC).

16th January 2018

Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder

Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above.

29th June 2017

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis

Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis (SM) indications.

2nd May 2017

Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia

Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD).

17th April 2017

Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.

2nd April 2017

Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer

Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer in post-menopausal women.

15th March 2017

Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC)

Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC).

5th February 2017

Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA)

Spinraza™ (nusinersen) is an anti-sense oligonucleotide indicated for treatment of spinal muscular atrophy (SMA) in paediatric and adult patients.

26th January 2017

Xultophy 100/3.6 for the Treatment of Type 2 Diabetes

Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes.

30th November 2016

Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection

Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment.

21st November 2016

Invokamet XR for the Treatment of Type 2 Diabetes in Adults

Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults.

16th November 2016

Defitelio (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease

Defitelio (defibrotide sodium) is an injectable drug developed by Jazz Pharmaceuticals, for the treatment of hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome, in adults and children with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

19th May 2016

Descovy (emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection

Descovy (emtricitabine200mg/tenofovir alafenamide25mg, F/TAF) is developed by Gilead sciences for the treatment of HIV-1 infection in adults and children above 12 years of age.

5th May 2016

Xeljanz XR (tofacitinib citrate) Modified Release Tablets For the Treatment of Rheumatoid Arthritis

Xeljanz XR (tofacitinib citrate) is an 11mg once-daily oral JAK inhibitor developed by Pfizer for the treatment of moderate to severe Rheumatoid Arthritis (RA).

10th March 2016

Briviact (brivaracetam) For the Treatment of Partial Onset Seizures

Briviact (brivaracetam) was developed by UCB for the treatment of partial onset of seizures in epilepsy patients over the age of 16.

3rd March 2016

Portrazza (necitumumab) for the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Portrazza (necitumumab) is a recombinant human lgG1 monoclonal antibody developed by Eli Lilly, for the treatment of metastatic squamous non-small cell lung cancer (NSCLC).

13th January 2016

Press Release

Regional Offices

Exploristics Ltd

Go Top